{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:27:18Z","timestamp":1792736838127,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The use of oncolytic viruses has emerged as a promising therapeutic approach due to the features of these viruses, which selectively replicate and destroy tumor cells while sparing normal cells. Although numerous oncolytic viruses have been developed for testing in solid tumors, only a few have been reported to target acute myeloid leukemia (AML) and overall patient survival has remained low. We previously developed the oncolytic adenovirus rAd5pz-zTRAIL-RFP-S\u039424E1a (A4), which carries the viral capsid protein IX linked to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and results in increased infection of cancer cells and improved tumor targeting. To further improve the therapeutic potential of A4 by enhancing the engagement of virus and leukemia cells, we generated a new version of A4, zA4, by coating A4 with additional soluble TRAIL that is fused with a leucine zipper-like dimerization domain (zipper). ZA4 resulted in enhanced infectivity and significant inhibition of the proliferation of AML cells from cell lines and primary patient samples that expressed moderate levels of TRAIL-related receptors. ZA4 also elicited enhanced anti-AML activity in vivo compared with A4 and an unmodified oncolytic adenoviral vector. In addition, we found that the ginsenoside Rh2 upregulated the expression of TRAIL receptors and consequently enhanced the antitumor activity of zA4. Our results indicate that the oncolytic virus zA4 might be a promising new agent for treating hematopoietic malignancies such as AML.<\/jats:p>","DOI":"10.1038\/s41392-020-0135-9","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T23:04:50Z","timestamp":1587683090000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia"],"prefix":"10.1038","volume":"5","author":[{"given":"Zixuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenmo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,24]]},"reference":[{"issue":"Suppl","key":"135_CR1","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.clml.2016.02.007","volume":"16","author":"NJ Short","year":"2016","unstructured":"Short, N. J. & Ravandi, F. Acute myeloid leukemia: past, present, and prospects for the future. Clin. Lymphoma Myeloma Leuk. 16(Suppl), S25\u2013S29 (2016).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"135_CR2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41392-019-0076-3","volume":"4","author":"T Wang","year":"2019","unstructured":"Wang, T. et al. Simultaneous cotargeting of ATR and RNA polymerase I transcription demonstrates synergistic antileukemic effects on acute myeloid leukemia. Signal Transduct. Target Ther. 4, 44 (2019).","journal-title":"Signal Transduct. Target Ther."},{"key":"135_CR3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","volume":"29","author":"A Burnett","year":"2011","unstructured":"Burnett, A., Wetzler, M. & Lowenberg, B. Therapeutic advances in acute myeloid leukemia. J. Clin. Oncol. 29, 487\u2013494 (2011).","journal-title":"J. Clin. Oncol."},{"key":"135_CR4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41392-019-0050-0","volume":"4","author":"I Nepstad","year":"2019","unstructured":"Nepstad, I. et al. Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. Signal Transduct. Target Ther. 4, 20 (2019).","journal-title":"Signal Transduct. Target Ther."},{"key":"135_CR5","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell, S. J., Peng, K. W. & Bell, J. C. Oncolytic virotherapy. Nat. Biotechnol. 30, 658\u2013670 (2012).","journal-title":"Nat. Biotechnol."},{"key":"135_CR6","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.mayocp.2014.04.003","volume":"89","author":"SJ Russell","year":"2014","unstructured":"Russell, S. J. et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin. Proc. 89, 926\u2013933 (2014).","journal-title":"Mayo Clin. Proc."},{"key":"135_CR7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood-2002-08-2508","volume":"102","author":"CM Thirukkumaran","year":"2003","unstructured":"Thirukkumaran, C. M. et al. Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood 102, 377\u2013387 (2003).","journal-title":"Blood"},{"key":"135_CR8","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/hep.29513","volume":"67","author":"CH Liu","year":"2018","unstructured":"Liu, C. H. et al. A multifunctional nanocarrier for efficient TRAIL-based gene therapy against hepatocellular carcinoma with desmoplasia in mice. Hepatology 67, 899\u2013913 (2018).","journal-title":"Hepatology"},{"key":"135_CR9","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1038\/leu.2009.219","volume":"23","author":"M Kim","year":"2009","unstructured":"Kim, M. et al. Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells. Leukemia 23, 2313\u20132317 (2009).","journal-title":"Leukemia"},{"key":"135_CR10","first-page":"107502","volume":"27","author":"CC Ma","year":"2019","unstructured":"Ma, C. C. et al. The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnol. Adv. 27, 107502 (2019).","journal-title":"Biotechnol. Adv."},{"key":"135_CR11","doi-asserted-by":"crossref","first-page":"E201","DOI":"10.3390\/cancers10060201","volume":"10","author":"AT Baker","year":"2018","unstructured":"Baker, A. T., Aguirre-Hernandez, C., Hallden, G. & Parker, A. L. Designer oncolytic adenovirus: coming of age. Cancers (Basel) 10, E201 (2018).","journal-title":"Cancers (Basel)"},{"key":"135_CR12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","volume":"132","author":"SN Waddington","year":"2008","unstructured":"Waddington, S. N. et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132, 397\u2013409 (2008).","journal-title":"Cell"},{"key":"135_CR13","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3390\/v2102290","volume":"2","author":"L Coughlan","year":"2010","unstructured":"Coughlan, L. et al. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2, 2290\u20132355 (2010).","journal-title":"Viruses"},{"key":"135_CR14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/sj.leu.2405034","volume":"22","author":"W Qian","year":"2008","unstructured":"Qian, W. et al. Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7\/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Leukemia 22, 361\u2013369 (2008).","journal-title":"Leukemia"},{"key":"135_CR15","doi-asserted-by":"crossref","first-page":"47287","DOI":"10.18632\/oncotarget.10075","volume":"7","author":"Z Wang","year":"2016","unstructured":"Wang, Z. et al. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route. Oncotarget 7, 47287\u201347301 (2016).","journal-title":"Oncotarget"},{"key":"135_CR16","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/91000","volume":"7","author":"K Ichikawa","year":"2001","unstructured":"Ichikawa, K. et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7, 954\u2013960 (2001).","journal-title":"Nat. Med."},{"key":"135_CR17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1074-7613(00)80212-5","volume":"12","author":"FC Kischkel","year":"2000","unstructured":"Kischkel, F. C. et al. Apo2L\/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12, 611\u2013620 (2000).","journal-title":"Immunity"},{"key":"135_CR18","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1158\/1078-0432.CCR-13-2305","volume":"20","author":"AS Gallouet","year":"2014","unstructured":"Gallouet, A. S. et al. COX-2-independent effects of celecoxib sensitize lymphoma B cells to TRAIL-mediated apoptosis. Clin. Cancer Res. 20, 2663\u20132673 (2014).","journal-title":"Clin. Cancer Res."},{"key":"135_CR19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pbiomolbio.2017.02.009","volume":"128","author":"K Selvarajoo","year":"2017","unstructured":"Selvarajoo, K. A systems biology approach to overcome TRAIL resistance in cancer treatment. Prog. Biophys. Mol. Biol. 128, 142\u2013154 (2017).","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"135_CR20","first-page":"3863","volume":"47","author":"T Ota","year":"1987","unstructured":"Ota, T. et al. Plant-glycoside modulation of cell surface related to control of differentiation in cultured B16 melanoma cells. Cancer Res. 47, 3863\u20133867 (1987).","journal-title":"Cancer Res."},{"key":"135_CR21","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1021\/acs.jafc.7b02299","volume":"65","author":"C Wang","year":"2017","unstructured":"Wang, C. et al. Ginsenoside 20(S)-Rh2 induces apoptosis and differentiation of acute myeloid leukemia cells: role of orphan nuclear receptor Nur77. J. Agric. Food Chem. 65, 7687\u20137697 (2017).","journal-title":"J. Agric. Food Chem."},{"key":"135_CR22","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1139\/Y07-099","volume":"85","author":"DD Kitts","year":"2007","unstructured":"Kitts, D. D., Popovich, D. G. & Hu, C. Characterizing the mechanism for ginsenoside-induced cytotoxicity in cultured leukemia (THP-1) cells. Can. J. Physiol. Pharm. 85, 1173\u20131183 (2007).","journal-title":"Can. J. Physiol. Pharm."},{"key":"135_CR23","first-page":"255","volume":"26","author":"B Yu","year":"2011","unstructured":"Yu, B. et al. Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects. Oncol. Rep. 26, 255\u2013264 (2011).","journal-title":"Oncol. Rep."},{"key":"135_CR24","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood-2009-03-208835","volume":"114","author":"R Alba","year":"2009","unstructured":"Alba, R. et al. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 114, 965\u2013971 (2009).","journal-title":"Blood"},{"key":"135_CR25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm.3107","volume":"19","author":"Z Xu","year":"2013","unstructured":"Xu, Z. et al. Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat. Med. 19, 452\u2013457 (2013).","journal-title":"Nat. Med."},{"key":"135_CR26","volume":"7","author":"Y Shi","year":"2018","unstructured":"Shi, Y., Pang, X., Wang, J. & Liu, G. NanoTRAIL-oncology: a strategic approach in cancer research and therapy. Adv. Health. Mater. 7, e1800053 (2018).","journal-title":"Adv. Health. Mater."},{"key":"135_CR27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2217\/nnm.11.186","volume":"7","author":"MR Duffy","year":"2012","unstructured":"Duffy, M. R., Parker, A. L., Bradshaw, A. C. & Baker, A. H. Manipulation of adenovirus interactions with host factors for gene therapy applications. Nanomedicine (Lond.) 7, 271\u2013288 (2012).","journal-title":"Nanomedicine (Lond.)"},{"key":"135_CR28","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1002\/adma.201301385","volume":"25","author":"LQ Pan","year":"2013","unstructured":"Pan, L. Q. et al. Novel conjugation of tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) with monomethyl auristatin E for efficient antitumor drug delivery. Adv. Mater. 25, 4718\u20134722 (2013).","journal-title":"Adv. Mater."},{"key":"135_CR29","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood-2008-09-178459","volume":"113","author":"RC Carlisle","year":"2009","unstructured":"Carlisle, R. C. et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 113, 1909\u20131918 (2009).","journal-title":"Blood"},{"key":"135_CR30","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2009-12-260026","volume":"116","author":"R Alba","year":"2010","unstructured":"Alba, R. et al. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 116, 2656\u20132664 (2010).","journal-title":"Blood"},{"key":"135_CR31","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/sj.cgt.7700597","volume":"10","author":"JY Seol","year":"2003","unstructured":"Seol, J. Y. et al. Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect. Cancer Gene Ther. 10, 540\u2013548 (2003).","journal-title":"Cancer Gene Ther."},{"key":"135_CR32","first-page":"734","volume":"59","author":"MM Keane","year":"1999","unstructured":"Keane, M. M. et al. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 59, 734\u2013741 (1999).","journal-title":"Cancer Res."},{"key":"135_CR33","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood-2007-09-114314","volume":"113","author":"M Fakler","year":"2009","unstructured":"Fakler, M. et al. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 113, 1710\u20131722 (2009).","journal-title":"Blood"},{"key":"135_CR34","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/abbs\/gmw049","volume":"48","author":"J Huang","year":"2016","unstructured":"Huang, J. et al. Ginsenoside Rh2 inhibits proliferation and induces apoptosis in human leukemia cells via TNF-alpha signaling pathway. Acta Biochim. Biophys. Sin. (Shanghai) 48, 750\u2013755 (2016).","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"key":"135_CR35","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s00277-017-3148-x","volume":"96","author":"D Yang","year":"2017","unstructured":"Yang, D., Zhang, X., Zhang, X. & Xu, Y. The progress and current status of immunotherapy in acute myeloid leukemia. Ann. Hematol. 96, 1965\u20131982 (2017).","journal-title":"Ann. Hematol."},{"key":"135_CR36","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1172\/JCI122287","volume":"130","author":"J Martinez-Quintanilla","year":"2019","unstructured":"Martinez-Quintanilla, J., Seah, I., Chua, M. & Shah, K. Oncolytic viruses: overcoming translational challenges. J. Clin. Invest. 130, 1407\u20131418 (2019).","journal-title":"J. Clin. Invest."},{"key":"135_CR37","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","volume":"18","author":"PK Bommareddy","year":"2018","unstructured":"Bommareddy, P. K., Shettigar, M. & Kaufman, H. L. Integrating oncolytic viruses in combination cancer immunotherapy. Nat. Rev. Immunol. 18, 498\u2013513 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"135_CR38","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.molcel.2017.01.021","volume":"65","author":"T Hartwig","year":"2017","unstructured":"Hartwig, T. et al. The TRAIL-induced cancer secretome promotes a tumor-supportive immune microenvironment via CCR2. Mol. Cell. 65, 730\u2013742 (2017). e735.","journal-title":"Mol. Cell."},{"key":"135_CR39","volume":"4","author":"G Li","year":"2014","unstructured":"Li, G. et al. CD123 targeting oncolytic adenoviruses suppress acute myeloid leukemia cell proliferation in vitro and in vivo. Blood Cancer J. 4, e194 (2014).","journal-title":"Blood Cancer J."},{"key":"135_CR40","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1038\/mt.2009.193","volume":"17","author":"TP Cripe","year":"2009","unstructured":"Cripe, T. P. et al. Targeting cancer-initiating cells with oncolytic viruses. Mol. Ther. 17, 1677\u20131682 (2009).","journal-title":"Mol. Ther."},{"key":"135_CR41","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/blood-2015-06-652503","volume":"127","author":"W Shen","year":"2016","unstructured":"Shen, W. et al. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Blood 127, 1449\u20131458 (2016).","journal-title":"Blood"},{"key":"135_CR42","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41401-019-0287-8","volume":"40","author":"HH Zhong","year":"2019","unstructured":"Zhong, H. H., Wang, H. Y., Li, J. & Huang, Y. Z. TRAIL-based gene delivery and therapeutic strategies. Acta Pharm. Sin. 40, 1373\u20131385 (2019).","journal-title":"Acta Pharm. Sin."},{"key":"135_CR43","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00262-012-1370-x","volume":"62","author":"Z Diao","year":"2013","unstructured":"Diao, Z. et al. TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4(+)CD25 (+) Treg apoptosis. Cancer Immunol. Immunother. 62, 653\u2013663 (2013).","journal-title":"Cancer Immunol. Immunother."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-0135-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-0135-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-0135-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T13:43:03Z","timestamp":1670247783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-0135-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["135"],"URL":"https:\/\/doi.org\/10.1038\/s41392-020-0135-9","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,24]]},"assertion":[{"value":"3 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethical Committee for Care and Use of Laboratory Animals at Jilin University. Informed consent was obtained from patients before sample collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"40"}}